DK0906426T3 - Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser - Google Patents

Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser

Info

Publication number
DK0906426T3
DK0906426T3 DK97923243T DK97923243T DK0906426T3 DK 0906426 T3 DK0906426 T3 DK 0906426T3 DK 97923243 T DK97923243 T DK 97923243T DK 97923243 T DK97923243 T DK 97923243T DK 0906426 T3 DK0906426 T3 DK 0906426T3
Authority
DK
Denmark
Prior art keywords
fibronectin
domain
antibodies
construction
specific
Prior art date
Application number
DK97923243T
Other languages
Danish (da)
English (en)
Inventor
Dario Neri
Barbara Carnemolla
Annalisa Siri
Enrica Balza
Patrizia Castellani
Alessandro Pini
Luciano Zardi
Greg Winter
Giovanni Neri
Laura Borsi
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of DK0906426T3 publication Critical patent/DK0906426T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK97923243T 1996-05-24 1997-05-23 Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser DK0906426T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods
PCT/GB1997/001412 WO1997045544A1 (fr) 1996-05-24 1997-05-23 Anticorps contre le domaine ed-b de la fibronectine, leur construction et leurs utilisations

Publications (1)

Publication Number Publication Date
DK0906426T3 true DK0906426T3 (da) 2007-09-10

Family

ID=10794298

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97923243T DK0906426T3 (da) 1996-05-24 1997-05-23 Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser

Country Status (29)

Country Link
US (3) US7273924B1 (fr)
EP (1) EP0906426B1 (fr)
JP (2) JP4750912B2 (fr)
KR (2) KR20050010081A (fr)
CN (1) CN100447159C (fr)
AT (1) ATE361364T1 (fr)
AU (1) AU729081B2 (fr)
BG (1) BG65138B1 (fr)
BR (1) BR9709350B1 (fr)
CA (1) CA2256308C (fr)
CZ (1) CZ295531B6 (fr)
DE (1) DE69737683T2 (fr)
DK (1) DK0906426T3 (fr)
EA (1) EA004329B1 (fr)
ES (1) ES2286831T3 (fr)
GB (1) GB9610967D0 (fr)
HK (1) HK1020990A1 (fr)
HU (1) HUP0200546A2 (fr)
IL (2) IL127216A0 (fr)
IS (1) IS2508B (fr)
NO (1) NO324904B1 (fr)
NZ (1) NZ333083A (fr)
PL (1) PL188557B1 (fr)
PT (1) PT906426E (fr)
SI (1) SI0906426T1 (fr)
SK (1) SK285916B6 (fr)
TR (1) TR199802416T2 (fr)
UA (1) UA74129C2 (fr)
WO (1) WO1997045544A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
ES2373966T3 (es) * 2000-02-24 2012-02-10 Philogen S.P.A. Composiciones y procedimientos para el tratamiento de la angiogénesis en lesiones patológicas.
AU4243201A (en) * 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
WO2001085777A2 (fr) 2000-05-09 2001-11-15 Greenville Hospital System Peptides therapeutiques formant des pores
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
ES2312478T3 (es) * 2000-09-07 2009-03-01 Bayer Schering Pharma Aktiengesellschaft Receptor del dominio edb de fibronectina (ii).
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
EP1461360B1 (fr) 2002-01-03 2010-08-18 Bayer Schering Pharma Aktiengesellschaft Conjugues comprenant un anticorps specifique du domaine ed-b de la fibronectine et leur utilisation pour detecter et traiter les tumeurs
EP2174958A1 (fr) * 2002-03-11 2010-04-14 Philogen S.p.A. Anticorps dérivés de l19 dirigé contre ed-b et le ciblage de la vascularisation tumorale
KR101257584B1 (ko) 2002-07-15 2013-04-23 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
BRPI0408315A (pt) 2003-03-14 2006-03-07 Wyeth Corp anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1702069A2 (fr) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukine-12 ciblee sur la fibronectine oncofoetale
US7943294B2 (en) 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1803814A1 (fr) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Procédé d'amélioration la capacité de sélection d'anticorps dans une bibliothèque d'affichage de phages
EP1925664A1 (fr) 2006-11-15 2008-05-28 Scil proteins GmbH Protéines de liaison artificielles basées sur une région modifiée de type hélice alpha de l'ubiquitine
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
EP2100621A1 (fr) 2008-03-10 2009-09-16 mivenion GmbH Conjugués de dendrimère de polyol de polyéther dotés de molécules effectrices pour le ciblage biologique
EP2116555A1 (fr) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Utilisation d'une molécule radiomarquée se liant spécifiquement à la fibronectine ED-B dans un procédé de traitement du lymphome Hodgkin
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
ES2441803T3 (es) 2009-12-14 2014-02-06 Scil Proteins Gmbh Un método para identificar proteínas de ubicuitina heteromultímeras modificadas con capacidad para unirse a ligandos
WO2011110490A1 (fr) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Procédé pour la production de fragments d'anticorps scfv marqués radioactivement, kits et compositions
WO2012171541A1 (fr) 2011-06-15 2012-12-20 Scil Proteins Gmbh Protéines hybrides humaines comportant des interférons et des protéines hétérodimériques modifiées par ubiquitine
WO2012172055A1 (fr) 2011-06-15 2012-12-20 Scil Proteins Gmbh Protéines liantes dimères obtenues à partir d'ubiquitines modifiées
US20150183846A1 (en) 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (fr) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Fragments d'ubiquitine en tant que moyens pour prolonger la demi-vie sérique
EP3029065B1 (fr) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Anticorps humains contre le domaine ed-b de la fibronectine et utilisations de ceux-ci
DK3253785T3 (da) 2015-02-06 2019-07-08 Navigo Proteins Gmbh Hidtil ukendte egfr-bindingsproteiner
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
CN108291915B (zh) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
JP7181612B2 (ja) 2016-08-11 2022-12-01 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング アルカリ安定性免疫グロブリン結合タンパク質
KR102338660B1 (ko) 2016-10-17 2021-12-10 화이자 인코포레이티드 항-edb 항체 및 항체-약물 접합체
EP3634999A1 (fr) 2017-06-07 2020-04-15 Philogen S.p.A. Protéines de fusion d'anticorps anti-facteur de croissance endothéliale vasculaire/anti-fibronectine
EP3689903A4 (fr) 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. Protéine se liant au domaine de la fibronectine b
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
EP3660039A1 (fr) 2018-11-30 2020-06-03 Philogen S.p.A. Immunoconjugués d'il2
WO2020070150A1 (fr) 2018-10-02 2020-04-09 Philogen S.P.A Immunoconjugués d'il2
JOP20220035A1 (ar) 2019-08-15 2023-01-30 Janssen Biotech Inc مواد وطرق لتحسين أجزاء المتغير أحادي السلسلة
EP4073111A1 (fr) 2019-12-11 2022-10-19 Cilag GmbH International Molécules de liaison multispécifiques comprenant des domaines de liaison ltbr et edb et leurs utilisations
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
WO2023131611A1 (fr) 2022-01-04 2023-07-13 Philogen S.P.A. Combinaison d'une immunocytokine comprenant l'il-12 et un inhibiteur de kinase
WO2024028258A1 (fr) 2022-08-01 2024-02-08 Philochem Ag Conjugués de fractions de liaison au psma avec des agents cytotoxiques
WO2024052333A1 (fr) 2022-09-06 2024-03-14 Philochem Ag Ligands multivalents de protéine d'activation des fibroblastes pour applications d'administration ciblée

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689598T2 (de) 1985-01-28 1994-06-30 Xoma Corp Arab-promoter und verfahren zur herstellung von polypeptiden einschliesslich cecropinen mittels mikrobiologischer verfahren.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
CA1341235C (fr) 1987-07-24 2001-05-22 Randy R. Robinson Assemblage modulaire de genes d'anticorps, anticorps prepares de cette facon, ainsi que leur usage
JPH02598A (ja) * 1987-10-09 1990-01-05 De La Rue Co Plc:The 集積回路カード
ATE140731T1 (de) 1988-01-11 1996-08-15 Xoma Corp Plasmidvektor mit pectatlyase-signalsequenz
IT1217724B (it) * 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) * 1988-09-14 1990-03-15 Fujita Gakuen 抗ｅｄ−ｂ抗体
JPH04169195A (ja) * 1990-10-31 1992-06-17 Fujita Gakuen 抗ｅｄ―ｂモノクローナル抗体
EP1136556B1 (fr) 1991-11-25 2005-06-08 Enzon, Inc. Procédé pour produire de protéines multivalents de fixation de l'antigène
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
WO1994007598A1 (fr) 1992-09-25 1994-04-14 Otsuka Pharmaceutical Factory, Inc. Adsorbant pour fibronectine cellulaire, separation et purification de fibronectine et purification du sang
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6015897A (en) 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO1996023816A1 (fr) 1995-02-01 1996-08-08 British Technology Group Limited Proteines radiomarquees
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
ES2373966T3 (es) 2000-02-24 2012-02-10 Philogen S.P.A. Composiciones y procedimientos para el tratamiento de la angiogénesis en lesiones patológicas.
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
EP1461360B1 (fr) 2002-01-03 2010-08-18 Bayer Schering Pharma Aktiengesellschaft Conjugues comprenant un anticorps specifique du domaine ed-b de la fibronectine et leur utilisation pour detecter et traiter les tumeurs
JP4169195B2 (ja) * 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置

Also Published As

Publication number Publication date
HK1020990A1 (en) 2000-05-26
JP4750912B2 (ja) 2011-08-17
ATE361364T1 (de) 2007-05-15
KR20050010081A (ko) 2005-01-26
BG102950A (en) 1999-08-31
SK161298A3 (en) 1999-07-12
CA2256308C (fr) 2012-03-13
GB9610967D0 (en) 1996-07-31
PL188557B1 (pl) 2005-02-28
US8703143B2 (en) 2014-04-22
US20140134182A1 (en) 2014-05-15
EP0906426B1 (fr) 2007-05-02
IL127216A (en) 2008-11-26
WO1997045544A1 (fr) 1997-12-04
AU2910197A (en) 1998-01-05
KR20060035812A (ko) 2006-04-26
BR9709350A (pt) 2000-01-04
DE69737683D1 (de) 2007-06-14
JP2000511416A (ja) 2000-09-05
SI0906426T1 (sl) 2007-10-31
IS4883A (is) 1998-10-29
IS2508B (is) 2009-04-15
US9096670B2 (en) 2015-08-04
CZ381598A3 (cs) 1999-03-17
DE69737683T2 (de) 2008-01-10
EP0906426A1 (fr) 1999-04-07
BR9709350B1 (pt) 2010-12-14
ES2286831T3 (es) 2007-12-01
CN100447159C (zh) 2008-12-31
US20080274099A1 (en) 2008-11-06
IL127216A0 (en) 1999-09-22
NO985459L (no) 1999-01-22
NO324904B1 (no) 2007-12-27
CA2256308A1 (fr) 1997-12-04
SK285916B6 (sk) 2007-11-02
PT906426E (pt) 2007-07-23
NZ333083A (en) 2000-05-26
BG65138B1 (bg) 2007-03-30
CZ295531B6 (cs) 2005-08-17
TR199802416T2 (xx) 1999-02-22
PL330075A1 (en) 1999-04-26
UA74129C2 (uk) 2005-11-15
JP2009050261A (ja) 2009-03-12
US7273924B1 (en) 2007-09-25
EA004329B1 (ru) 2004-04-29
HUP0200546A2 (en) 2002-07-29
KR100741452B1 (ko) 2007-07-20
EA199801043A1 (ru) 1999-04-29
AU729081B2 (en) 2001-01-25
NO985459D0 (no) 1998-11-23
CN1219968A (zh) 1999-06-16

Similar Documents

Publication Publication Date Title
DK0906426T3 (da) Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser
DK0488470T3 (da) Fremgangsmåde til fremstilling af antistoffer
DK0724456T3 (da) CD40-Antistoffer
DE69838061D1 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
ES2177632T3 (es) Purificacion de anticuerpos.
DE69939820D1 (de) Internalisierende erbb2 antikörper
ATE208820T1 (de) Humanisierte antikoerper
ATE324381T1 (de) Mutiertes scfv-fragment des okt-3 antikörpers
DE69934597D1 (de) Formstabile bindemittelsysteme
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
ATE476989T1 (de) Humanisierter monoklonaler antikörper gegen von- willebrand faktor
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
DE50114321D1 (de) REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)
DK0975601T3 (da) Fremgangsmåde til fremstilling af butylthio-isoquinolin og mellemprodukter derfor
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
WO1999028465A3 (fr) Molecules pias reconnaissant et fixant les proteines stat et procedes d'utilisation
DK1161522T3 (da) Fremgangsmåde til isolering af CD8+-celler og beslægtede hybridomaceller, antistoffer og polypeptider